CoChat

Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers

Pope, Laura E., Khalil, M. H., Berg, James E., Stiles, Mark, Yakatan, Gerald J., Sellers, Edward M. · 2004 · The Journal of Clinical Pharmacology
Cited by 122

The DOI matches its Crossref record.

Abstract

Dextromethorphan (DM) pharmacological properties predict that the widely used cough suppressant could be used to treat several neuronal disorders, but it is rapidly metabolized after oral dosing. To find out whether quinidine (Q), a CYP2D6 inhibitor, could elevate and prolong DM plasma profiles, 2 multiple‐dose studies identified the lowest oral dose of Q that could be used in a fixed combination with 3 doses of DM. A multiple‐dose study in healthy subjects with an extensive or a poor enzyme metabolizer phenotype evaluated the safety and pharmacokinetic profile of a selected fixed‐dose combination (AVP‐923). Study 1 randomized 46 healthy subjects, who were extensive CYP2D6 metabolizers, to receive 0, 2.5, 10, 25, 50, or 75 mg Q twice daily in combination with 30 mg DM for 7 days. Plasma and urine samples were collected after the first and last doses for the assay of DM, dextrorphan (DX), and Q. Study 2 randomized 65 healthy extensive CYP2D6 metabolizers to 8 groups given twice‐daily 45‐ or 60‐mg DM doses combined with 0, 30, 45, or 60 mg Q for 7 days. The effects of increasing Q were not different with doses greater than 25 mg, whereas lower doses showed a dose‐related increase in plasma DM concentrations. Urinary ratios of DM/DX showed a Q dose‐ and time‐related increase in the number of subjects converted to the poor metabolizer phenotype that reached 100% on day 3 of dosing with 25 mg Q. Results from both studies indicated that 25 to 30 mg Q is adequate to maximally suppress O‐demethylation of DM. Study 3 evaluated 7 extensive metabolizers and 2 poor metabolizers given an oral capsule every 12 hours containing 30 mg Q combined with 30 mg DM. DM plasma AUC values increased in both groups of subjects during the 8‐day study. The mean urinary metabolic ratio (DM/DX) increased at least 27‐fold in extensive metabolizers by day 8. There was no effect of Q on urinary metabolic ratios in poor metabolizers. Safety evaluations, including electrocardiograms, indicated that the combination was well tolerated, with no difference between extensive and poor metabolizer phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270004269521

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. 10.1038/clpt.1992.77 · DOI
  2. 10.2174/1389450013348335 · DOI · Paper page
  3. Liu Y, 2003, Dextromethorphan protects dopaminergic neurons against inflammation‐mediated degeneration through inhibition of microglial activation, J Pharmacol Exp Ther., 21, 21
  4. 10.1016/S0024-3205(02)02309-3 · DOI
  5. Desmeules JA, 1999, Contribution of cytochrome P‐4502D6 phenotype to the neuromodulatory effects of dextromethorphan, J Pharmacol Exp Ther., 288, 607, 10.1016/S0022-3565(24)37996-0 · DOI
  6. 10.1016/0028-3908(87)90275-9 · DOI · Paper page
  7. 10.1016/0006-8993(88)91497-7 · DOI
  8. 10.1016/0014-2999(93)90849-D · DOI
  9. 10.1111/j.1600-0404.1997.tb00231.x · DOI
  10. 10.1097/00002826-199619020-00009 · DOI
  11. 10.1097/00002826-198908000-00010 · DOI
  12. 10.1007/PL00007759 · DOI
  13. 10.1016/0304-3959(94)90056-6 · DOI · Paper page
  14. 10.1016/S0002-9343(99)00009-1 · DOI · Paper page
  15. 10.1007/BF03018952 · DOI
  16. 10.1097/00000542-200205000-00005 · DOI · Paper page
  17. 10.1016/S0304-3959(01)00455-9 · DOI
  18. 10.1097/00002508-200209000-00002 · DOI
  19. 10.1016/S0885-3924(99)00125-6 · DOI
  20. 10.1038/clpt.1985.235 · DOI · Paper page
  21. 10.1016/0006-8993(87)90070-9 · DOI · Paper page
  22. Duche J‐C, 1993, Dextromethorphan O‐demethylation and dextrorphan glucuronidation in a French population, Int J Clin Pharmacol Ther Toxicol., 31, 392
  23. 10.1023/A:1015925225766 · doi:10.1023/a:1015925225766
  24. 10.3171/jns.1996.84.5.0860 · DOI
  25. 10.1016/S0140-6736(84)92591-1 · DOI
  26. 10.1097/00007691-198804000-00021 · doi:10.1097/00007691-198804000-00021
  27. 10.1097/00008571-199808000-00006 · DOI
  28. 10.1111/j.1365-2125.1986.tb05251.x · DOI
  29. Smith R, 1995, The treatment of affective lability with dextromethorphan, Neurology, 54, 604P
  30. 10.1007/BF00558166 · doi:10.1007/bf00558166
  31. 10.1002/(SICI)1099-081X(1998110)19:8<541::AID-BDD138>3.0.CO;2-8 · doi:10.1002/(sici)1099-081x(1998110)19:8<541::aid-bdd138>3.0.co;2-8
  32. Rakhit A, 1982, Improved liquid‐chromatographic assay of quinidine and its metabolites in biological fluids, Clin Chem, 28, 1505, 10.1093/clinchem/28.7.1505 · doi:10.1093/clinchem/28.7.1505
  33. 10.1201/b14095 · DOI · Paper page
  34. 10.1056/NEJM199801013380107 · DOI
  35. 10.1111/j.1600-0404.1996.tb00181.x · DOI
  36. 10.1046/j.1365-2125.1999.00029.x · DOI
  37. 10.1016/S0009-9236(96)90056-9 · DOI
  38. 10.1097/00004714-199508000-00005 · DOI · Paper page
  39. 10.1002/ana.410360619 · DOI
  40. 10.1111/j.2042-7158.1998.tb06914.x · DOI
  41. 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B · DOI · Paper page
  42. 10.1016/S0024-3205(02)01799-X · doi:10.1016/s0024-3205(02)01799-x
  43. 10.1161/01.CIR.99.4.552 · DOI · Paper page
  44. 10.1016/S0022-3565(24)37075-2 · DOI · Paper page
  45. 10.1067/mcp.2000.109156 · DOI · Paper page
  46. 10.1097/00004714-199808000-00014 · DOI
  47. 10.1016/0002-8703(78)90200-4 · doi:10.1016/0002-8703(78)90200-4

Cited by

See all 122

Metadata

Authors
Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2004-10
Volume
44
Issue
10
Pages
1132-1142
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2000782600
Cited by
122
References
0
FWCI
5.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. https://app.cochat.ai/papers/10.1177/0091270004269521
The paper
Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M. (2004). Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270004269521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.